Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design, Setting, and Participants
2.2. Information Collection
2.3. Vaccination
2.4. Outcomes
2.5. Statistical Analyses
3. Results
3.1. Characteristics of the Subjects
3.2. Clinical Outcomes of the Subjects
3.3. Overall VE against HZ and PHN
3.4. VE against HZ in the Stratified Analyses
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Levin, M.J.; Smith, J.G.; Kaufhold, R.M.; Barber, D.; Hayward, A.R.; Chan, C.Y.; Chan, I.S.; Li, D.J.; Wang, W.; Keller, P.M.; et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J. Infect. Dis. 2003, 188, 1336–1344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dworkin, R.H.; Schmader, K.E.; Goldstein, E.J.C. Treatment and prevention of postherpetic neuralgia. Clin. Infect. Dis. 2003, 36, 877–882. [Google Scholar] [CrossRef]
- Drolet, M.; Brisson, M.; Schmader, K.E.; Levin, M.J.; Johnson, R.; Oxman, M.N.; Patrick, D.; Blanchette, C.; Mansi, J.A. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: A prospective study. Can. Med Assoc. J. 2010, 182, 1731–1736. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Johnson, R.W.; Bouhassira, D.; Kassianos, G.; Leplege, A.; Schmader, K.E.; Weinke, T. The impact of herpes zoster and postherpetic neuralgia on quality-of-life. BMC Med. 2010, 8, 37. [Google Scholar] [CrossRef] [Green Version]
- Lydick, E.; Epstein, R.S.; Himmelberger, D.; White, C.J. Herpes zoster and quality of life: A self-limited disease with severe impact. Neurology 1995, 45 (Suppl. 8), S52–S53. [Google Scholar] [CrossRef] [PubMed]
- Gnann, J.W., Jr.; Whitley, R.J. Herpes zoster. N. Engl. J. Med. 2002, 347, 340–346. [Google Scholar] [CrossRef]
- Kost, R.G.; Straus, S.E. Postherpetic neuralgia—pathogenesis, treatment, and prevention. N. Engl. J. Med. 1996, 335, 32–42. [Google Scholar] [CrossRef]
- Forbes, H.J.; Thomas, S.L.; Smeeth, L.; Clayton, T.; Farmer, R.; Bhaskaran, K.; Langan, S.M. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016, 157, 30–54. [Google Scholar] [CrossRef]
- Sato, K.; Adachi, K.; Nakamura, H.; Asano, K.; Watanabe, A.; Adachi, R.; Kiuchi, M.; Kobayashi, K.; Matsuki, T.; Kaise, T.; et al. Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study. J. Dermatol. 2017, 44, 414–422. [Google Scholar] [CrossRef]
- Takao, Y.; Miyazaki, Y.; Okeda, M.; Onishi, F.; Yano, S.; Gomi, Y.; Ishikawa, T.; Okuno, Y.; Mori, Y.; Asada, H.; et al. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: The SHEZ study. J. Epidemiology 2015, 25, 617–625. [Google Scholar] [CrossRef] [Green Version]
- Imafuku, S.; Matsuki, T.; Mizukami, A.; Goto, Y.; de Souza, S.; Jégou, C.; Bianco, V.; Rosillon, D.; Ito, C.; Curran, D.; et al. Burden of herpes zoster in the Japanese population with immunocompromised/chronic disease conditions: Results from a cohort study claims database from 2005–2014. Dermatol. Ther. 2019, 9, 117–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hata, A.; Kuniyoshi, M.; Ohkusa, Y. Risk of herpes zoster in patients with underlying diseases: A retrospective hospital-based cohort study. Infection 2011, 39, 537–544. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Papagianni, M.; Metallidis, S.; Tzlomalos, K. Herpes zoster and diabetes mellitus: A review. Diabetes Ther. 2018, 9, 545–550. [Google Scholar] [CrossRef] [PubMed]
- Otani, N.; Shima, M.; Yamamoto, T.; Okuno, T. Effect of routine varicella immunization on the epidemiology and immunogenicity of varicella and shingles. Viruses 2022, 14, 588. [Google Scholar] [CrossRef]
- Asada, H. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study. Vaccine 2019, 37, 6776–6781. [Google Scholar] [CrossRef]
- Levin, M.J.; Oxman, M.N.; Zhang, J.H.; Johnson, G.R.; Stanley, H.; Hayward, A.R.; Caulfield, M.J.; Irwin, M.; Smith, J.G.; Clair, J.; et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 2008, 197, 825–835. [Google Scholar] [CrossRef] [Green Version]
- Oxman, M.; Levin, M.; Johnson, G.; Schmader, K.; Straus, S.; Gelb, L.; Arbeit, R.; Simberkoff, M.; Gershon, A.; Davis, L.; et al. Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Eng. J. Med. 2005, 352, 2271–2284. [Google Scholar] [CrossRef] [Green Version]
- Schmader, K.E.; Levin, M.J.; Gnann, J.W.; McNeil, S.A.; Vesikari, T.; Betts, R.F.; Keay, S.; Stek, J.E.; Bundick, N.D.; Su, S.-C.; et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin. Infect. Dis. 2012, 54, 922–928. [Google Scholar] [CrossRef] [Green Version]
- Ohfuji, S.; Ito, K.; Inoue, M.; Ishibashi, M.; Kumashiro, H.; Hirota, Y.; Kayano, E.; Ota, N. Safety of live attenuated varicella-zoster vaccine in patients with underlying illness compared with healthy adults: A prospective cohort. BMC Infect. Dis. 2019, 19, 95. [Google Scholar] [CrossRef]
- Tseng, H.F.; Smith, N.; Harpaz, R.; Bialek, S.R.; Sy, L.S.; Jacobsen, S.J. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011, 305, 160–166. [Google Scholar] [CrossRef] [Green Version]
- Baxter, R.; Bartlett, J.; Fireman, B.; Marks, M.; Hansen, J.; Lewis, E.; Aukes, L.; Chen, Y.; Klein, N.P.; Saddier, P. Long-term effectiveness of the live zoster vaccine in preventing shingles: A cohort study. Am. J. Epidemiol. 2018, 187, 161–169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Langan, S.M.; Smeeth, L.; Margolis, D.J.; Thomas, S.L. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: A cohort study. PLoS Med. 2013, 10, e1001420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marin, M.; Yawn, B.P.; Hales, C.M.; Wollan, P.C.; Bialek, S.R.; Zhang, J.; Kurland, M.J.; Harpaz, R. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum. Vaccin. Immunother. 2015, 11, 1157–1164. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Langan, S.M.; Thomas, S.L.; Smeeth, L.; Margolis, D.J.; Nitsch, D. Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease. Nephrol. Dial. Transplant. 2016, 31, 2095–2098. [Google Scholar] [CrossRef] [Green Version]
- Tseng, H.F.; Tartof, S.; Harpaz, R.; Luo, Y.; Sy, L.S.; Hetcher, R.C.; Jacobsen, S.J. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin. Infect. Dis. 2014, 59, 913–919. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mullane, K.M.; A Morrison, V.; Camacho, L.H.; Arvin, A.; A McNeil, S.; Durrand, J.; Campbell, B.; Su, S.-C.; Chan, I.S.F.; Parrino, J.; et al. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: A two-arm, randomised, double-blind, phase 3 trial. Lancet Infect. Dis. 2019, 19, 1000–1012. [Google Scholar] [CrossRef]
- Walker, J.L.; Andrews, N.J.; Amirthalingam, G.; Forbes, H.; Langan, S.M.; Thomas, S.L. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine 2018, 36, 2371–2377. [Google Scholar] [CrossRef]
- Jevšnik, M.; Lusa, L.; Uršič, T.; Glinšek Biškup, U.; Petrovec, M. Detection of herpes simplex and varicella-zoster virus from skin lesions: Comparison of RT-PCR and isothermal amplification for rapid identification. Diagn. Microbiol. Infect. Dis. 2020, 97, 115015. [Google Scholar] [CrossRef]
Variables | Vaccinated Group (n = 1098) | Unvaccinated Group (n = 518) | p-Value a |
---|---|---|---|
Age (years) | |||
Median [range] | 67 (53–89) | 67 (50–89) | 0.96 |
Age (years) | |||
Older than 70 years | 436 (40) | 197 (38) | 0.52 |
Male | 563 (51) | 220 (42) | <0.01 |
Comorbidities b | 472 (43) | 266 (51) | <0.01 |
Hypertension | 299 (27) | 164 (32) | 0.06 |
Dyslipidemia | 112 (10) | 49 (9) | 0.64 |
Diabetes mellitus | 127 (12) | 69 (13) | 0.31 |
Chronic renal diseases | 4 (0) | 14 (3) | <0.01 |
Autoimmune diseases c | 5 (0) | 12 (2) | <0.01 |
Respiratory diseases d | 15 (1) | 15 (3) | 0.04 |
Malignant solid tumor | 22 (2) | 19 (4) | 0.04 |
Other diseases | 58 (5) | 39 (8) | 0.08 |
Medication | 477 (43) | 268 (52) | <0.01 |
Variables | Vaccinated Group (n = 1098) | Unvaccinated Group (n = 518) | p-Value a |
---|---|---|---|
HZ | 26 (2.4) | 22 (4.2) | 0.04 |
PHN | 3 (0.3) | 2 (0.4) | 0.66 |
Outcome | No. of Outcome in Vaccinated Group (n = 1098) | No. of Outcome in Unvaccinated Group (n = 518) | Crude VE (95% CI) | Adjusted VE (95% CI) a |
---|---|---|---|---|
HZ | 26 (2.4) | 22 (4.2) | 45% (3–69%) | 41% (−6 to 67%) |
PHN | 3 (0.3) | 2 (0.4) | 29% (−324 to 88%) | 16% (−408 to 86%) |
Stratified Category | Number of Outcome/Vaccinated Group (%) | Number of Outcome/Unvaccinated Group (%) | Crude VE (95% CI) | Adjusted VE (95% CI) a | p for Interaction |
---|---|---|---|---|---|
Comorbidities (−) | 14/626 (2) | 11/252 (4) | 50% (−12 to 78%) | 40% (−36 to 73%) | 0.82 |
Comorbidities (+) | 12/472 (3) | 11/266 (4) | 40% (−39 to 74%) | 39% (−42 to 73%) | |
Male | 9/563 (2) | 6/220 (3) | 42% (−65 to 80%) | 34% (−91 to 77%) | 0.98 |
Female | 17/535 (3) | 16/298 (5) | 42% (−16 to 71%) | 40% (−22 to 70%) | |
<70 years | 17/662 (3) | 15/321 (5) | 46% (−9 to 74%) | 43% (−56 to 79%) | 0.53 |
≥70 years | 9/436 (2) | 7/197 (4) | 38% (−28 to 70%) | 40% (−67 to 78%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Matsumoto, K.; Ohfuji, S.; Inohara, K.; Akechi, M.; Kumashiro, H.; Ishibashi, M.; Irie, S.; Hirota, Y. Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study. Vaccines 2023, 11, 259. https://doi.org/10.3390/vaccines11020259
Matsumoto K, Ohfuji S, Inohara K, Akechi M, Kumashiro H, Ishibashi M, Irie S, Hirota Y. Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study. Vaccines. 2023; 11(2):259. https://doi.org/10.3390/vaccines11020259
Chicago/Turabian StyleMatsumoto, Kazuhiro, Satoko Ohfuji, Kana Inohara, Masateru Akechi, Hiroko Kumashiro, Motoki Ishibashi, Shin Irie, and Yoshio Hirota. 2023. "Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study" Vaccines 11, no. 2: 259. https://doi.org/10.3390/vaccines11020259
APA StyleMatsumoto, K., Ohfuji, S., Inohara, K., Akechi, M., Kumashiro, H., Ishibashi, M., Irie, S., & Hirota, Y. (2023). Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study. Vaccines, 11(2), 259. https://doi.org/10.3390/vaccines11020259